Articles from Annovis Bio Inc.

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSEANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer’s & Parkinson’s Drug Development Summit happening on March 18-20 in Boston, MA.

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June.

MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps.

MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer’s (AD) and Parkinson’s disease (PD), today announced the data from its Phase II/III Alzheimer study of buntanetap in mild to moderate AD patients. Based on these data, the Company plans to conduct a pivotal Phase III trial in biomarker-positive early AD patients.

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.

Further look at earlier Phase 1b study by ADCS unveils confirmatory data

MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024. 

MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD). 

MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications. This application follows the U.S. Provisional Application No. 63/440,890 which was filed on January 24, 2023.

MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease. This adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results.

BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to participate in the 139th Yale CEO Summit in New York on December 11-12, 2023. 

BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024.

BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. 

BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that AD phase II/III study of its lead compound buntanetap has exceeded full enrollment. 

BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSEANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments.

Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients